Tokyo Tape
Sign in
← Sumitomo Chemical

Quarterly report · Q1

4005.TEDINET S100RJX5
Period2023-04-01 → 2023-06-30
Filed2023-08-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥563.1bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥2.90T2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥774.1bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income−¥71.7bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥66.3bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax−¥49.9bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥231m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥113.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥33.2bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.0bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥51.2bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥46.9bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥85.1bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥4.37Tat 2023-06-30Cons.Assets IFRS
Total assets¥4.17Tat 2023-03-31Cons.Assets IFRS
Total assets¥4.67Tat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.82Tat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥2.68Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.55Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.86Tat 2022-06-30Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.34Tat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥323.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥498.6bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥131.9bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥111.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥42.6bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥13.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥19.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥46.0bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥142.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥178.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥11.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-20.272023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥4.272022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.812022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥4.272022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
Equity ratio28.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.1%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.8%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥37.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥17.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥20.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥2.4bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥27.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥27.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥4.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-06-30¥78.8bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-06-30¥73.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥5.5bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.0bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-06-30¥193.7bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-06-30¥192.4bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥21.0bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥103.5bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥102.7bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥762m
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30−¥7.0bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-06-30¥94.6bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-06-30¥94.5bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥110m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-06-30¥6.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥83.0bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥83.0bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥33.3bn
—segment totalrevenue2023-04-01 → 2023-06-30¥553.6bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥545.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥7.7bn
—segment totalsegment profit2023-04-01 → 2023-06-30−¥51.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥31.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥14.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥17.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥3.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.5bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-06-30¥91.3bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-06-30¥86.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.8bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-06-30¥6.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-06-30¥240.0bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-06-30¥238.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥153.5bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥152.6bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥945m
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥21.9bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-06-30¥114.8bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-06-30¥114.7bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥116m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-06-30¥15.8bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-06-30¥14.1bn
—segment totalrevenue2022-04-01 → 2022-06-30¥767.3bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥759.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥68.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 840
ItemContextValueUnit
Profit loss before tax IFRSPrior1YTDDuration113656000000JPY
Profit loss before tax IFRSCurrentYTDDuration-49862000000JPY
Income tax expense IFRSPrior1YTDDuration28548000000JPY
Income tax expense IFRSCurrentYTDDuration1320000000JPY
Profit loss IFRSPrior1YTDDuration85108000000JPY
Profit loss IFRSCurrentYTDDuration-51182000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration69992000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration-33153000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration15116000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration-18029000000JPY
Profit loss IFRSPrior1YTDDuration85108000000JPY
Profit loss IFRSCurrentYTDDuration-51182000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration42.81
Basic earnings loss per share IFRSCurrentYTDDuration-20.27
Diluted earnings loss per share IFRSPrior1YTDDuration－
Diluted earnings loss per share IFRSCurrentYTDDuration－
Profit loss IFRSPrior1YTDDuration85108000000JPY
Profit loss IFRSCurrentYTDDuration-51182000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-7173000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration36468000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-62000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-5000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-811000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration407000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-8046000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration36870000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration7970000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration816000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration92422000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration81672000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration14932000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration6321000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration115324000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration88809000000JPY
Other comprehensive income IFRSPrior1YTDDuration107278000000JPY
Other comprehensive income IFRSCurrentYTDDuration125679000000JPY
Comprehensive income IFRSPrior1YTDDuration192386000000JPY
Comprehensive income IFRSCurrentYTDDuration74497000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration147880000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration63422000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration44506000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration11075000000JPY
Comprehensive income IFRSPrior1YTDDuration192386000000JPY
Comprehensive income IFRSCurrentYTDDuration74497000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember89699000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember27089000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember974382000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-8343000000JPY
Equity IFRSPrior2YearInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember82682000000JPY
Equity IFRSPrior2YearInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass